Clinical Trial Diversity: User Fee Bill Wants FDA’s Assessment Of Whether It Needs More Authority

 
• By Brenda Sandburg
  
Generate a summary of this article
Listen to this article
Beta

HHS is to evaluate the need for FDA authority to mandate postapproval studies or postmarket surveillance if sponsors do not meet diversity enrollment goals. By contrast, the DEPICT Act would have given the agency the authority to do so.

Diversity
FDA user fee bill includes provisions on improving diversity in clinical trials • Source: Shutterstock

Legislation to extend the Food and Drug Administration’s user fee programs has taken a softer approach to the agency’s oversight of clinical trial diversity than another bill pending in Congress. Rather than giving the FDA authority to mandate postmarketing studies if a sponsor does not meet its diversity enrollment goals, the legislation calls for the Secretary of the Department of Health and Human Services to evaluate whether the agency needs such authority.

The House FDA user fees package, released by the Democratic and Republican leadership of the House Energy and Commerce...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Diversity & Inclusion

Diversity Action Plans: What To Submit And When

 
• By Nielsen Hobbs

With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.

Clinical Trial Diversity Action Plans Need Timely FDA Feedback, Groups Say

 
• By Sue Sutter

The agency also should explain the potential consequences for sponsors if enrollment goals are not met, stakeholders say in comments on the DAP draft guidance. Some commenters urged the FDA to apply waiver criteria flexibly, especially for rare diseases.

Pharma Warming Up To Benefits Of Australia’s Teletrials Initiative

 
• By Vibha Sharma

The Australian teletrials program has surpassed expectations at its mid-way point and is being used by drug and device sponsors looking to enhance trial participant recruitment and retention by enabling access to rural, regional and remote areas.

More from Clinical Trials

UK Expedites Cost Negotiations For Companies Conducting ATMP & Early Phase Trials

 
• By Neena Brizmohun

Companies dealing with commercial costings or contracts with the National Health Service for early phase clinical trials or trials of advanced therapy medicinal products should soon be able to conclude their negotiations more quickly.

Clinical Trial Diversity Action Plans Need Timely FDA Feedback, Groups Say

 
• By Sue Sutter

The agency also should explain the potential consequences for sponsors if enrollment goals are not met, stakeholders say in comments on the DAP draft guidance. Some commenters urged the FDA to apply waiver criteria flexibly, especially for rare diseases.

How To Decarbonize Pharma R&D

 
• By Francesca Bruce

As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.